The U.S. Food and Drug Administration (FDA) has assembled an advisory panel on peptides that includes experts known for promoting unproven chemicals, a move that aligns with the interests of Health and Human Services Secretary Robert F. Kennedy Jr., who has long advocated for alternative and unverified treatments.
Panel Composition Raises Concerns
The panel, tasked with evaluating the safety and efficacy of peptide-based therapies, features several individuals who have publicly endorsed the use of unproven peptides for conditions ranging from aging to chronic disease. Critics argue that these experts lack rigorous scientific credentials and may have conflicts of interest due to their ties to companies marketing these products.
According to internal documents reviewed by The Associated Press, the panel includes at least three members who have received funding from or served as advisors to peptide manufacturers. One member, a naturopathic physician, has promoted peptide therapies on social media without FDA approval.
RFK Jr.'s Influence
Secretary Kennedy, who took office in 2025, has been a vocal proponent of alternative medicine and has questioned traditional regulatory frameworks. His appointment of like-minded officials to key health agencies has sparked debate about the balance between innovation and patient safety. “The inclusion of these experts reflects a broader shift in the administration’s approach to health regulation,” said Dr. Emily Carter, a former FDA official. “There is a risk that unproven treatments could be fast-tracked without adequate evidence.”
Peptide Popularity and Risks
Peptides, short chains of amino acids, have gained popularity in recent years for purported benefits in muscle growth, weight loss, and anti-aging. However, many of these claims lack robust clinical data, and the FDA has issued warnings about unapproved peptide products. The panel’s recommendations could influence future FDA decisions on peptide regulation, potentially opening the door to broader access.
Consumer advocacy groups have expressed alarm. “Patients deserve treatments backed by science, not hype,” said Sarah Johnson of the Center for Safe Medicine. “Stacking a panel with proponents of unproven therapies undermines the FDA’s credibility.”
Next Steps
The panel is scheduled to meet in July to discuss guidelines for peptide clinical trials and marketing. The FDA has stated that it will consider the panel’s advice but emphasized that final decisions will be based on scientific evidence. Secretary Kennedy’s office did not respond to requests for comment.
